Joseph Zakrzewski - Onxeo SA Non-Executive Chairman of the Board
| C4X Stock | EUR 0.11 0.01 8.33% |
Chairman
Mr. Joseph S. Zakrzewski was appointed NonExecutive Chairman of the Board of Directors of Onxeo SA, effective as of the end of January 2016. He has more than 25 years of experience in the healthcare industry. His career started with Eli Lilly Company in the USA. He joined as process engineer with responsibility for biologics development and manufacturing, became Senior Financial Analyst and Head of Manufacturing and Development, then Manager and Director of Corporationrationrate Business Development, before being appointed VP Global Corporationrationrate Business Development . He was Chief Operating Officer of Reliant Pharmaceuticals, and then joined the biotechnology company Xcellerex as CEO . From 2010 to 2013, he was Chairman and CEO of Amarin Corporation, where he remains a director. He has also been a venture partner at Orbimed Advisors, one of the leading VC funds dedicated to the healthcare industry . Joseph Zakrzewski is a board member with several biotechnology companies in Europe and in the USA, public and private, including Insulet Corporationrationration, Amarin Corporationrationration, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc., and SiteOne Therapeutics. He received a BS in Chemical Engineering and a MS degree in Biochemical Engineering from Drexel University. He has an MBA in Finance from the University of Indiana. since 2016.
| Age | 56 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Joseph Zakrzewski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Zakrzewski against Onxeo SA stock is an integral part of due diligence when investing in Onxeo SA. Joseph Zakrzewski insider activity provides valuable insight into whether Onxeo SA is net buyers or sellers over its current business cycle. Note, Onxeo SA insiders must abide by specific rules, including filing SEC forms every time they buy or sell Onxeo SA'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Zakrzewski over two months ago Exercise or conversion by Joseph Zakrzewski of 14150 shares of Cyteir Therapeutics subject to Rule 16b-3 | ||
Joseph Zakrzewski over three months ago Sale by Joseph Zakrzewski of 100000 shares of AN2 Therapeutics | ||
Joseph Zakrzewski over six months ago Purchase by Joseph Zakrzewski of 1000 shares of Cyteir Therapeutics | ||
Joseph Zakrzewski over six months ago Purchase by Joseph Zakrzewski of 1700 shares of Cyteir Therapeutics |
Onxeo SA Management Efficiency
The company has return on total asset (ROA) of (0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Bruce Karsh | NorAm Drilling AS | 60 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 |
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | ||
| Russell Greig, Independent Member of the Board | ||
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | ||
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | ||
| Huiping Jiang, VP Assurance | ||
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | ||
| Thomas Hofstaetter, Independent Member of the Board | ||
| MD MPH, CEO Pres | ||
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | ||
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | ||
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | ||
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | ||
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | ||
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | ||
| David Solomon, Independent Member of the Board | ||
| Louis Kayitalire, Vice President Head of Research & Development | ||
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | ||
| Daniele GuyotCaparros, Independent Member of the Board | ||
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | ||
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | ||
| Patrick Langlois, Independent Chairman of the Board | ||
| Graham Dixon, Chief Scientific Officer, Head of Research & Development, Member of the Executive Committee | ||
| Joseph Zakrzewski, Non-Executive Chairman of the Board | ||
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | ||
| Nicolas Fellmann, CFO Director |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Onxeo SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Onxeo SA's short interest history, or implied volatility extrapolated from Onxeo SA options trading.
Pair Trading with Onxeo SA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onxeo SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onxeo SA will appreciate offsetting losses from the drop in the long position's value.Moving against Onxeo Stock
| 0.74 | KBIA | KB Financial Group | PairCorr |
| 0.72 | NOVA | Novo Nordisk AS | PairCorr |
| 0.65 | MBG | Mercedes Benz Group | PairCorr |
| 0.64 | DBPE | Xtrackers LevDAX | PairCorr |
| 0.5 | PQ9 | PT Bank Mandiri | PairCorr |
The ability to find closely correlated positions to Onxeo SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onxeo SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onxeo SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onxeo SA to buy it.
The correlation of Onxeo SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onxeo SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onxeo SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onxeo SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Onxeo SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |